ReNAgade Therapeutics is a technology company.
ReNAgade Therapeutics has raised $300.0M across 1 funding round.
ReNAgade Therapeutics has raised $300.0M in total across 1 funding round.
ReNAgade Therapeutics has raised $300.0M in total across 1 funding round.
ReNAgade Therapeutics's investors include Creacion Ventures, MPM Capital.
ReNAgade Therapeutics is a biotechnology company founded in 2021 that developed RNA medicines using novel delivery platforms for coding, editing, and gene insertion to treat diseases anywhere in the body.[1][2][3] Headquartered in Cambridge, Massachusetts, it launched publicly in May 2023 with a record $300 million Series A funding led by F2 Ventures and MPM Capital's BioImpact, enabling rapid scaling to about 100 employees, many from Moderna and Alnylam.[1][2][5] The company targeted extra-hepatic delivery challenges via lipid nanoparticles (LNPs), RNA editing tools, and collaborations like with Orna Therapeutics on circular RNA, serving unmet needs in tissues such as immune, kidney, and muscle cells.[2][3][4] In May 2024, ReNAgade was acquired by Orna Therapeutics, integrating its technologies to advance in vivo CAR RNA therapies and gene editing, with former CEO Amit Munshi taking over as Orna's CEO.[1][4][6]
This positions ReNAgade as a key innovator in RNA therapeutics, solving delivery limitations that restrict RNA drugs beyond the liver, with strong early momentum from patents (over 100 filed) and expert leadership before its acquisition solidified Orna's leadership in circular RNA.[2][4]
ReNAgade emerged from MPM Capital's startup incubator in 2021, debuting publicly in May 2023 after quietly raising and deploying its massive $300M Series A.[1][2] CEO Amit Munshi, former president and CEO of Arena Pharmaceuticals, led the effort alongside co-founder Brian Goodman, assembling a team of RNA veterans from Moderna and Alnylam.[2][3] The idea stemmed from RNA delivery bottlenecks—described by Munshi as a "bugaboo" for the field—spurring an "all-in-one" platform combining LNPs for broad tissue targeting, RNA editing, and partnerships like with Orna for circular RNA.[2][3]
Pivotal early moves included investing in GanNA Bio (also 2021-founded) for glycobiology-based extra-hepatic delivery, licensing tech from Stanford's Carolyn Bertozzi (2022 Nobel laureate) and others, then integrating GanNA's founders as advisors.[3] This groundwork fueled over 100 patents and hiring blitz, culminating in Orna's acquisition in May 2024 to merge strengths in delivery and circular RNA expression.[1][4][6]
ReNAgade stood out in RNA therapeutics through these key strengths:
Post-acquisition, these feed Orna's pipeline for panCAR in vivo therapies and gene editing.[4][6]
ReNAgade rode the post-COVID RNA revolution, capitalizing on mRNA vaccine successes to push beyond liver delivery—a key barrier blocking RNA's full potential for systemic diseases.[2] Timing was ideal: 2023's funding surge amid biotech recovery, outpacing rivals like Orbital's $270M round, amid rising demand for extra-hepatic solutions in oncology, rare diseases, and beyond.[1][2][4]
Market tailwinds include advancing circular RNA (oRNA) for durable expression and LNPs refined from vaccines, plus glycobiology for precision targeting.[3][4] ReNAgade influenced the ecosystem by accelerating Orna's dominance in next-gen RNA, unifying delivery/editing with oRNA to challenge cell therapies, and drawing top talent/IP that reshapes RNA as a "new frontier" eclipsing traditional methods.[3][4]
Post-acquisition, ReNAgade's assets propel Orna toward clinical milestones in panCAR in vivo RNA therapies and expanded gene editing, targeting massive unmet needs in hard-to-treat diseases.[4][6] Rising trends like AI-driven RNA design (e.g., Biostate's tools) and glycobiology will amplify their edge, with synergies multiplying R&D speed.[1][3]
Expect Orna (with ReNAgade integrated) to lead RNA's shift to systemic, editable medicines, evolving influence from delivery innovator to platform powerhouse—unlocking RNA's "limitless potential" where others falter.[3][4] This builds on their 2023 launch hook: solving delivery to treat disease anywhere.
ReNAgade Therapeutics has raised $300.0M across 1 funding round. Most recently, it raised $300.0M Series A in May 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2023 | $300.0M Series A | Creacion Ventures, MPM Capital |